BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Cisplatin, rs3825942, PPARA, Metabolism of xenobiotics, Leukemia, Lung, Neocentromeres)
Bookmark Forward

QuickView for AZD7762 (compound)


Genetic Markers

Most Correlated Genes

  1. XIST
  2. RBP4
  3. WIF1
  4. SERPINA3
  5. MUC4
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. regulation of nitrogen compound metabolic process
  2. organic cyclic compound binding
  3. cytosol
  4. heterocyclic compound binding
  5. cell periphery
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Embryonic stem H1 cells treated with aphidicolin alone or in combination with AZD7762
  2. L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
  3. L1000 CMAP - Skeletal muscle SKL.C cells treated with small molecule perturbagens
  4. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
  5. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway.
  2. Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.
  3. Chk1/2 inhibitor AZD7762 blocks the growth of preantral follicles by inducing apoptosis, suppressing…
  4. Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomid…
  5. Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
  2. Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients…
  3. Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinoteca…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.